BioPharm International
June 01, 2012
Issue PDF
25
6
Celebrating 25 Years of BioPharma Innovation
June 01, 2012
Guest Editorial
25
6
BIO is calling for a more patient-centric approach to user-fee reauthorization.
June 01, 2012
Features
25
6
Implementing quality by design makes the determination of quality metrics across CMOs and sponsors essential.
June 01, 2012
Features
25
6
A review of new biologic drug approvals over the years, featuring highlights from 2010 and 2011.
June 01, 2012
Manufacturing Best Practices
25
6
Leading industry collaborators outline top 10 best practices for human error reduction.
June 01, 2012
Features
25
6
In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.
June 01, 2012
Compliance Notes
25
6
The contract provider needs to know as much as the NDA holder.
June 01, 2012
Boot Camp Business Guide
25
6
Mike Clayman, CEO of Flexion Therapeutics, talks about his company's strategy to focus on a single therapeutic area.
June 01, 2012
Features
25
6
Panayiotis P. Constantinides of Biopharmaceutical & Drug Delivery Consulting on growth of nanoparticle delivery systems.
June 01, 2012
Features
25
6
A review of key industry shifts and promises for the future.
June 01, 2012
Manufacturing Best Practices
25
6
The authors discuss a new, rapid immunoassay for the detection of biomarkers.
June 01, 2012
Features
25
6
Charles H. Squires of Pfenex discusses advances in expression platform solutions.
June 01, 2012
Final Word
25
6
Formulators and developers are at the heart of the industry's basic premise-they are saving lives.
June 01, 2012
Features
25
6
Industry experts discuss significant achievements. Plus: What's in store for the future.
May 21, 2012
Online Exclusive
25
6
In this online extra, Board Members comment on major industry changes over the past few decades.